301 related articles for article (PubMed ID: 20621693)
1. Complement activation on platelets: implications for vascular inflammation and thrombosis.
Peerschke EI; Yin W; Ghebrehiwet B
Mol Immunol; 2010 Aug; 47(13):2170-5. PubMed ID: 20621693
[TBL] [Abstract][Full Text] [Related]
2. Diminished expression of β2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia.
Zhu X; Zhang J; Wang Q; Fu H; Chang Y; Kong Y; Lv M; Xu L; Liu K; Huang X; Zhang X
Ann Hematol; 2018 Apr; 97(4):641-654. PubMed ID: 29350259
[TBL] [Abstract][Full Text] [Related]
3. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies.
Peerschke EI; Yin W; Alpert DR; Roubey RA; Salmon JE; Ghebrehiwet B
Lupus; 2009 May; 18(6):530-8. PubMed ID: 19395455
[TBL] [Abstract][Full Text] [Related]
4. Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions.
Karpman D; Ståhl AL; Arvidsson I; Johansson K; Loos S; Tati R; Békássy Z; Kristoffersson AC; Mossberg M; Kahn R
Adv Exp Med Biol; 2015; 865():19-42. PubMed ID: 26306441
[TBL] [Abstract][Full Text] [Related]
5. Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome.
Lonati PA; Scavone M; Gerosa M; Borghi MO; Pregnolato F; Curreli D; Podda G; Femia EA; Barcellini W; Cattaneo M; Tedesco F; Meroni PL
Front Immunol; 2019; 10():773. PubMed ID: 31031764
[TBL] [Abstract][Full Text] [Related]
6. Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in Systemic Lupus Erythematosus.
Gartshteyn Y; Mor A; Shimbo D; Khalili L; Kapoor T; Geraldino-Pardilla L; Alexander RV; Conklin J; Dervieux T; Askanase AD
Clin Immunol; 2021 Jul; 228():108755. PubMed ID: 33984497
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series.
Lusa A; Carlson A
Lupus; 2018 Sep; 27(10):1723-1728. PubMed ID: 29673280
[TBL] [Abstract][Full Text] [Related]
8. Blood platelets activate the classical pathway of human complement.
Peerschke EI; Yin W; Grigg SE; Ghebrehiwet B
J Thromb Haemost; 2006 Sep; 4(9):2035-42. PubMed ID: 16961611
[TBL] [Abstract][Full Text] [Related]
9. Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia.
Sun S; Urbanus RT; Ten Cate H; de Groot PG; de Laat B; Heemskerk JWM; Roest M
Cells; 2021 Dec; 10(12):. PubMed ID: 34943895
[TBL] [Abstract][Full Text] [Related]
10. Complement activation in platelet concentrates is surface-dependent and modulated by the platelets.
Gyongyossy-Issa MI; McLeod E; Devine DV
J Lab Clin Med; 1994 Jun; 123(6):859-68. PubMed ID: 8201264
[TBL] [Abstract][Full Text] [Related]
11. Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients.
van Dijk WEM; Brandwijk ON; Heitink-Polle KMJ; Schutgens REG; van Galen KPM; Urbanus RT
Blood Rev; 2021 May; 47():100774. PubMed ID: 33213987
[TBL] [Abstract][Full Text] [Related]
12. Increase of C3a is Associated with Hemorrhagic Propensity in Patients with Immune Thrombocytopenia.
Ge J; Wang L; Li J; Hu Y; Xu Q; Chen Y; Hou R; Ruan M; Xia R; Zeng Q
Clin Lab; 2017 Apr; 63(4):765-771. PubMed ID: 28397467
[TBL] [Abstract][Full Text] [Related]
13. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome.
Breen KA; Seed P; Parmar K; Moore GW; Stuart-Smith SE; Hunt BJ
Thromb Haemost; 2012 Mar; 107(3):423-9. PubMed ID: 22234447
[TBL] [Abstract][Full Text] [Related]
14. Role of C3 cleavage in monocyte activation during extracorporeal circulation.
Rinder CS; Rinder HM; Johnson K; Smith M; Lee DL; Tracey J; Polack G; Higgins P; Yeh CG; Smith BR
Circulation; 1999 Aug; 100(5):553-8. PubMed ID: 10430771
[TBL] [Abstract][Full Text] [Related]
15. Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus.
Martin-Rodriguez S; Reverter JC; Tàssies D; Espinosa G; Heras M; Pino M; Escolar G; Diaz-Ricart M
Lupus; 2015 Oct; 24(11):1143-9. PubMed ID: 25824235
[TBL] [Abstract][Full Text] [Related]
16. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura.
Peerschke EI; Andemariam B; Yin W; Bussel JB
Br J Haematol; 2010 Feb; 148(4):638-45. PubMed ID: 19925495
[TBL] [Abstract][Full Text] [Related]
17. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome.
Pierangeli SS; Vega-Ostertag ME; González EB
Expert Rev Mol Med; 2007 Nov; 9(30):1-15. PubMed ID: 17997880
[TBL] [Abstract][Full Text] [Related]
18. Platelet activation leads to activation and propagation of the complement system.
Del Conde I; Crúz MA; Zhang H; López JA; Afshar-Kharghan V
J Exp Med; 2005 Mar; 201(6):871-9. PubMed ID: 15781579
[TBL] [Abstract][Full Text] [Related]
19. VWF, Platelets and the Antiphospholipid Syndrome.
Huang S; Ninivaggi M; Chayoua W; de Laat B
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919627
[TBL] [Abstract][Full Text] [Related]
20. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP).
Najaoui A; Bakchoul T; Stoy J; Bein G; Rummel MJ; Santoso S; Sachs UJ
Eur J Haematol; 2012 Feb; 88(2):167-74. PubMed ID: 21985182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
